Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...

Patients benefit from access to the advanced treatments created at Johns Hopkins. Our clinical trials are scientific studies that advance cancer care and prove the effectiveness of a new medication or ...